Evidence map›Paper›PMID 30550569›Full record

ArticlePLoS neglected tropical diseases2018

Economic impact of dengue in Mexico considering reported cases for 2012 to 2016.

Adriana Zubieta-Zavala, Malaquias López-Cervantes, Guillermo Salinas-Escudero, Adrian Ramírez-Chávez, José Ramos Castañeda, Sendy Isarel Hernández-Gaytán, Juan Guillermo López Yescas, Luis Durán-Arenas

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Markers of prolonged hospitalisation in severe dengue.PLoS neglected tropical diseases · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. From Surveillance To Control: Evaluation of A Larvicide Intervention AgainstJournal of the American Mosquito Control Association · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adriana Zubieta-ZavalaFaculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Malaquias López-CervantesFaculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Guillermo Salinas-EscuderoCenter for Economic Studies and Social Health, Children's Hospital of Mexico Federico Gómez, Ministry of Health, Mexico City, Mexico.
Adrian Ramírez-ChávezPrivate Practice, Mexico City, Mexico.
José Ramos CastañedaDepartamento de Arbovirus, National Institute of Public Health, Cuernavaca, Mexico.
Sendy Isarel Hernández-GaytánFaculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Juan Guillermo López YescasMedical Affairs, Sanofi Pasteur Latin America, Mexico City, Mexico.
Luis Durán-ArenasFaculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiven that dengue disease is growing and may progress to dengue hemorrhagic fever (DHF), data on economic cost and disease burden are important. However, data for Mexico are limited. METHODOLOGY/PRINCIPAL

findingsBurden of dengue fever (DF) and DHF in Mexico was assessed using official databases for epidemiological information, disabilities weights from Shepard et al, the reported number of cases and deaths, and costs. Overall costs of dengue were summed from direct medical costs to the health system, cost of dengue to the patient (out-of-pocket expenses [medical and non-medical], indirect costs [loss of earnings, patient and/or caregiver]), and other government expenditures on prevention/surveillance. The first three components, calculated as costs per case by a micro-costing approach (PAATI; program, actions, activities, tasks, inputs), were scaled up to overall cost using epidemiology data from official databases. PAATI was used to calculate cost of vector control and prevention, education, and epidemiological surveillance, based on an expert consensus and normative construction of an ideal scenario. Disability-adjusted life years (DALYs) for Mexico in 2016 were calculated to be 2283.46 (1.87 per 100,000 inhabitants). Overall economic impact of dengue in Mexico for 2012 was US$144 million, of which US$44 million corresponded to direct medical costs and US$5 million to the costs from the patient's perspective. The estimated cost of prevention/surveillance was calculated with information provided by federal government to be US$95 million. The overall economic impact of DF and DHF showed an increase in 2013 to US$161 million and a decrease to US$133, US$131 and US$130 million in 2014, 2015 and 2016, respectively. CONCLUSIONS/SIGNIFICANCE: The medical and economic impact of dengue were in agreement with other international studies, and highlight the need to include governmental expenditure for prevention/surveillance in overall cost analyses given the high economic impact of these, increasing the necessity to evaluate its effectiveness.

Indexed as

AdolescentAdultAgedCaregiversChildChild, PreschoolDengueGovernment ProgramsHealth Care CostsHealth ExpendituresHumansInfantMexicoMiddle AgedPersons with DisabilitiesQuality-Adjusted Life Years

Identifiers

PMID30550569
PMCPMC6310288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.